Mesenchymal Stromal Cell-Based Therapy for Dry Eye: Current Status and Future Perspectives

Overview

Journal Cell Transplant

Specialties Cell Biology
General Surgery

Date 2022 Nov 18

PMID 36398793

Authors

Yuting Jiang

Shu Lin

Yingying Gao

Affiliations

Soon will be listed here.

Abstract

Dry eye is one of the most common chronic diseases in ophthalmology. It affects quality of life and has become a public health problem that cannot be ignored. The current treatment methods mainly include artificial tear replacement therapy, anti-inflammatory therapy, and local immunosuppressive therapy. These treatments are mainly limited to improvement of ocular surface discomfort and other symptoms. In recent years, regenerative medicine has developed rapidly, and ophthalmologists are working on new methods to treat dry eye. Mesenchymal stromal cells (MSCs) have anti-inflammatory, tissue repair, and immune regulatory effects, and have become a promising tool for the treatment of dry eye. These effects can also be produced by MSC-derived exosomes (MSC-Exos). As a cell-free therapy, MSC-Exos are hypoimmunogenic, serve more stable entities, and compared with MSCs, reduce the safety risks associated with the injection of live cells. This article reviews current knowledge about MSCs and MSC-Exos, and highlights the latest progress and future prospects of MSC-based therapy in dry eye treatment.

Citing Articles

Mesenchymal Stem Cell-Sourced Exosomes as Potentially Novel Remedies for Severe Dry Eye Disease.

Harrell C, Djonov V, Volarevic A, Arsenijevic A, Volarevic V J Ophthalmol. 2025; 2025():5552374.

PMID: 39839752 PMC: 11748739. DOI: 10.1155/joph/5552374.

Identification of glutamine as a potential therapeutic target in dry eye disease.

Chen X, Zhang C, Peng F, Wu L, Zhuo D, Wang L Signal Transduct Target Ther. 2025; 10(1):27.

PMID: 39837870 PMC: 11751114. DOI: 10.1038/s41392-024-02119-1.

Molecular Mechanisms Responsible for Mesenchymal Stem Cell-Dependent Attenuation of Tear Hyperosmolarity and Immune Cell-Driven Inflammation in the Eyes of Patients with Dry Eye Disease.

Harrell C, Djonov V, Volarevic A, Arsenijevic A, Volarevic V Diseases. 2024; 12(11).

PMID: 39589943 PMC: 11592843. DOI: 10.3390/diseases12110269.

Multidimensional immunotherapy for dry eye disease: current status and future directions.

Huang D, Li Z Front Ophthalmol (Lausanne). 2024; 4:1449283.

PMID: 39554604 PMC: 11564177. DOI: 10.3389/fopht.2024.1449283.

Current Strategies and Therapeutic Applications of Mesenchymal Stem Cell-Based Drug Delivery.

Matsuzaka Y, Yashiro R Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931374 PMC: 11206583. DOI: 10.3390/ph17060707.

References

cejkova J, Trosan P, Cejka C, Lencova A, Zajicova A, Javorkova E . Suppression of alkali-induced oxidative injury in the cornea by mesenchymal stem cells growing on nanofiber scaffolds and transferred onto the damaged corneal surface. Exp Eye Res. 2013; 116:312-23. DOI: 10.1016/j.exer.2013.10.002. View

da Silva Meirelles L, Maria Fontes A, Covas D, Caplan A . Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009; 20(5-6):419-27. DOI: 10.1016/j.cytogfr.2009.10.002. View

Calonge M, Perez I, Galindo S, Nieto-Miguel T, Lopez-Paniagua M, Fernandez I . A proof-of-concept clinical trial using mesenchymal stem cells for the treatment of corneal epithelial stem cell deficiency. Transl Res. 2018; 206:18-40. DOI: 10.1016/j.trsl.2018.11.003. View

Marote A, Teixeira F, Mendes-Pinheiro B, Salgado A . MSCs-Derived Exosomes: Cell-Secreted Nanovesicles with Regenerative Potential. Front Pharmacol. 2016; 7:231. PMC: 4971062. DOI: 10.3389/fphar.2016.00231. View

Du Y, Funderburgh M, Mann M, SundarRaj N, Funderburgh J . Multipotent stem cells in human corneal stroma. Stem Cells. 2005; 23(9):1266-75. PMC: 1941788. DOI: 10.1634/stemcells.2004-0256. View

Lu X, Li N, Zhao L, Guo D, Yi H, Yang L . Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype. Exp Eye Res. 2020; 191:107905. PMC: 8612174. DOI: 10.1016/j.exer.2019.107905. View

Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G . Stem Cell-Derived Extracellular Vesicles and Immune-Modulation. Front Cell Dev Biol. 2016; 4:83. PMC: 4992732. DOI: 10.3389/fcell.2016.00083. View

Albertsmeyer A, Kakkassery V, Spurr-Michaud S, Beeks O, Gipson I . Effect of pro-inflammatory mediators on membrane-associated mucins expressed by human ocular surface epithelial cells. Exp Eye Res. 2009; 90(3):444-51. PMC: 2880853. DOI: 10.1016/j.exer.2009.12.009. View

Wang G, Cao K, Liu K, Xue Y, Roberts A, Li F . Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells. Cell Death Differ. 2017; 25(7):1209-1223. PMC: 6030103. DOI: 10.1038/s41418-017-0006-2. View

10.

Lee M, Ko A, Ko J, Lee H, Kim M, Wee W . Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye. Mol Ther. 2014; 23(1):139-46. PMC: 4426793. DOI: 10.1038/mt.2014.159. View

11.

Shi B, Qi J, Yao G, Feng R, Zhang Z, Wang D . Mesenchymal stem cell transplantation ameliorates Sjögren's syndrome via suppressing IL-12 production by dendritic cells. Stem Cell Res Ther. 2018; 9(1):308. PMC: 6225717. DOI: 10.1186/s13287-018-1023-x. View

12.

Shen T, Zheng Q, Shen J, Li Q, Song X, Luo H . Effects of Adipose-derived Mesenchymal Stem Cell Exosomes on Corneal Stromal Fibroblast Viability and Extracellular Matrix Synthesis. Chin Med J (Engl). 2018; 131(6):704-712. PMC: 5865317. DOI: 10.4103/0366-6999.226889. View

13.

Martinez H, Molina-Lopez J, Gonzalez-Garza M, Moreno-Cuevas J, Caro-Osorio E, Gil-Valadez A . Stem cell transplantation in amyotrophic lateral sclerosis patients: methodological approach, safety, and feasibility. Cell Transplant. 2013; 21(9):1899-907. DOI: 10.3727/096368911X582769. View

14.

Lin D, Halilovic A, Yue P, Bellner L, Wang K, Wang L . Inhibition of miR-205 impairs the wound-healing process in human corneal epithelial cells by targeting KIR4.1 (KCNJ10). Invest Ophthalmol Vis Sci. 2013; 54(9):6167-78. DOI: 10.1167/iovs.12-11577. View

15.

Dartt D, McCarthy D, Mercer H, Kessler T, Chung E, Zieske J . Localization of nerves adjacent to goblet cells in rat conjunctiva. Curr Eye Res. 1995; 14(11):993-1000. DOI: 10.3109/02713689508998520. View

16.

Basu S, Hertsenberg A, Funderburgh M, Burrow M, Mann M, Du Y . Human limbal biopsy-derived stromal stem cells prevent corneal scarring. Sci Transl Med. 2014; 6(266):266ra172. PMC: 4398334. DOI: 10.1126/scitranslmed.3009644. View

17.

Sugaya S, Sakimoto T, Shoji J, Sawa M . Regulation of soluble interleukin-6 (IL-6) receptor release from corneal epithelial cells and its role in the ocular surface. Jpn J Ophthalmol. 2011; 55(3):277-282. DOI: 10.1007/s10384-011-0002-x. View

18.

Thery C, Zitvogel L, Amigorena S . Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8):569-79. DOI: 10.1038/nri855. View

19.

Xian P, Hei Y, Wang R, Wang T, Yang J, Li J . Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. Theranostics. 2019; 9(20):5956-5975. PMC: 6735367. DOI: 10.7150/thno.33872. View

20.

Pflugfelder S, de Paiva C, Moore Q, Volpe E, Li D, Gumus K . Aqueous Tear Deficiency Increases Conjunctival Interferon-γ (IFN-γ) Expression and Goblet Cell Loss. Invest Ophthalmol Vis Sci. 2015; 56(12):7545-50. PMC: 4669202. DOI: 10.1167/iovs.15-17627. View